small molecule

INOMAX

NITRIC OXIDE

Loss of exclusivityNovember 2036latest FDA-listed patent expiry
CompanyMALLINCKRODT PHARMACEUTICALS IRELAND LTD

Drug detail

Brand nameINOMAX
Active ingredientNITRIC OXIDE
Strength800PPM
Dosage formGAS
RouteINHALATION
ModalitySmall molecule
FDA approvalDecember 1999
Marketing statusRX

Listed patents

PatentExpiresType
9770570*PEDNovember 2036
9770570May 2036use U-2148
9279794*PEDAugust 2035
9279794February 2035product
8776795*PEDJuly 2031
8776794*PEDJuly 2031
8573209*PEDJuly 2031
8573210*PEDJuly 2031
9265911*PEDJuly 2031
9408993*PEDJuly 2031
9295802*PEDJuly 2031
8291904*PEDJuly 2031
9265911January 2031product
8291904January 2031product
8776794January 2031product
8573209January 2031product
8573210January 2031product
9295802January 2031product
9408993January 2031product
8776795January 2031product
11931377*PEDDecember 2029
8282966*PEDDecember 2029
8293284*PEDDecember 2029
8431163*PEDDecember 2029
8795741*PEDDecember 2029
8846112*PEDDecember 2029
11931377June 2029substance, product
8431163June 2029use U-1286
8795741June 2029use U-1286
8846112June 2029use U-1286
8293284June 2029use U-1286
8282966June 2029use U-1286

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

INOMAX patent cliff — loss of exclusivity November 2036 | CliffBio